Refine
Has Fulltext
- yes (50) (remove)
Is part of the Bibliography
- yes (50) (remove)
Year of publication
- 2022 (50) (remove)
Document Type
- Journal article (48)
- Doctoral Thesis (2)
Language
- English (50) (remove)
Keywords
- multiple myeloma (5)
- Aspergillus (3)
- COVID-19 (3)
- apoptosis (3)
- deep learning (3)
- theranostics (3)
- C-X-C motif chemokine receptor 4 (2)
- CADe (2)
- CXCR4 (2)
- NAFLD (2)
- NASH (2)
- PET (2)
- [68Ga]PentixaFor (2)
- bone marrow immune-microenvironment (2)
- cancer (2)
- cholestasis (2)
- colonoscopy (2)
- endoluminal (2)
- endoradiotherapy (2)
- invasive pulmonary aspergillosis (2)
- negative pressure (2)
- quality of life (2)
- scleroderma (2)
- systemic sclerosis (2)
- vacuum-assisted closure (2)
- 3D printing (1)
- ARONJ (1)
- Alpelisib (1)
- Aspergillus fumigatus (1)
- B cell culture (1)
- B-cell lymphoma (1)
- BRAF mutation (1)
- CA19-9 (1)
- CAPA (1)
- CMR (1)
- Crohn’s disease (1)
- DNA damage (1)
- Dara-KDT-P(A)CE (1)
- EAE (1)
- FIB-4 (1)
- GLP-1 (1)
- German Hepatitis C-Registry (1)
- GvHD (1)
- HCV infection (1)
- HD (1)
- HSC (1)
- Hippo signaling (1)
- Immunantwort (1)
- Kono-S anastomosis (1)
- Li-Fraumeni syndrome (1)
- M30 (1)
- MEDAS (1)
- MTB (1)
- MTX (1)
- MUST-Score (1)
- Multiple myeloma (1)
- R-CHOP (1)
- RYGB (1)
- Rhizopus (1)
- Risikofaktoren (1)
- S100A8/S100A9 (1)
- SARS-CoV-2 (1)
- SF-12 (1)
- STS (1)
- T cells (1)
- TNF (1)
- TNF receptor associated factor 2 (TRAF2) (1)
- TNF-related apoptosis-inducing ligand (1)
- TNFR2 (1)
- Th17 cells (1)
- Tumorimmunologie (1)
- YAP (1)
- [177Lu]/[90Y]PentixaTher (1)
- [177Lu]PentixaTher (1)
- [90Y]PentixaTher (1)
- [\(^{68}\)Ga]Ga-FAPI (1)
- acute hypobaric hypoxia (1)
- adhesion molecule (1)
- adrenocortical carcinoma (1)
- adverse events (1)
- agar diffusion test (1)
- agonist (1)
- alloSCT patients (1)
- anastomotic leak (1)
- anastomotic leakage (1)
- annotation (1)
- antiphospholipid syndrome (1)
- antiresorptive drug-related osteonecrosis of the jaw (1)
- aplastic anemia (1)
- artificial intelligence (1)
- at-home sampling (1)
- autologous hematopoietic stem cell transplantation (1)
- automation (1)
- autophagy (1)
- beta-oxidation (1)
- biomarker (1)
- bone marrow failure (1)
- bone marrow homing (1)
- breakthrough infection (1)
- c-reactive protein (1)
- calprotectin (1)
- cancer care (1)
- cancer metabolism (1)
- cancer predisposition (1)
- cancer prevention (1)
- cancer stem cells (1)
- cardiac thrombi (1)
- caspase-3 (1)
- cell death (1)
- cell of origin (1)
- cellular inhibitor of apoptosis 1/2 (cIAP1/2) (1)
- chenodeoxycholate (1)
- chimeric antigen receptor (1)
- cytochrome P450 3A4 (CYP3A4) (1)
- cytokines (1)
- cytopenia (1)
- dabrafenib (1)
- depression (1)
- diagnostics (1)
- direct-acting antiviral (1)
- drug monitoring (1)
- drug–drug interactions (DDIs) (1)
- endoscopic (1)
- endoscopy (1)
- esophageal perforation (1)
- fatigue (1)
- fibroblast activation protein (1)
- fibrosis (1)
- fluorescence in situ hybridization (FISH) (1)
- fungal sinusitis (1)
- galectin-2 (1)
- gastric bypass (1)
- gastric emptying (1)
- gastroenterology (1)
- gastrointestinal perforation (1)
- glecaprevir/pibrentasvir (1)
- graft versus host disease (1)
- granulocytes (1)
- hematopoietic stem cells (1)
- hepatitis C virus (1)
- hepatocellular carcinoma (1)
- host response (1)
- hydroxy-dabrafenib (1)
- ileocecal resection (1)
- immune control (1)
- immune impairment (1)
- immune response (1)
- immunophenotyping (1)
- immunosuppression (1)
- individualized surgery (1)
- inflammation marker (1)
- instrument (1)
- intervention (1)
- invasive fungal infection (1)
- keratin-18 (1)
- liraglutide (1)
- liver (1)
- liver fibrosis (1)
- lymphoma (1)
- machine learning (1)
- malnutrition (1)
- matrix metallopeptidase-1 (1)
- melanoma (1)
- memory B cells (1)
- mindfulness (1)
- mixed infection (1)
- mycophenolate (1)
- myofibroblast (1)
- necroptosis (1)
- non-interventional (1)
- nuclear factor ‘kappa-light-chain-enhancer’ of activated B-cells (NFκB) (1)
- nutritional counseling (1)
- nutritional medical needs (1)
- nutritional risk screening (1)
- obesity (1)
- object detection (1)
- observational (1)
- oncology (1)
- oncology outpatients (1)
- operating platform (1)
- oral microbiome (1)
- osteonecrosis of the jaw (1)
- osteoradionecrosis (1)
- outbreak (1)
- outcomes research (1)
- outreach (1)
- pancreatic adenocarcinoma (PDAC) (1)
- pancreatic neoplasms (1)
- participation in clinical trials (1)
- pathogenic TP53 germline variant (1)
- patient access (1)
- patient-reported outcomes (1)
- peptide tyrosine tyrosine (PYY) (1)
- peptide tyrosine tyrosine 3-36 (PYY\(_{3-36}\)) (1)
- pharmacokinetics (1)
- phosphatidyl-inositol-3-kinase p110 alpha (1)
- physical activity (1)
- physiologically based pharmacokinetic (PBPK) modeling (1)
- poly(ADP-ribose) polymerase inhibitors (1)
- polyp (1)
- population pharmacokinetics (1)
- posaconazole (1)
- precision medicine (1)
- precision oncology (1)
- preoperative planning (1)
- prospective (1)
- psychology (1)
- psychosocial (1)
- radioligand therapy (1)
- real world data (1)
- real world evidence (1)
- refractory (1)
- regulatory T cells (1)
- rheumatoid arthritis (1)
- risk factors (1)
- rituximab (1)
- ruxolitinib (1)
- salvage (1)
- sarcoma (1)
- serum retention (1)
- stable isotope breath tests (1)
- steatosis (1)
- surgical manipulator (1)
- surgical therapy (1)
- systemic therapy (1)
- target validation (1)
- targeted therapies (1)
- tocilizumab (1)
- trabectedin (1)
- trametinib (1)
- transcriptome profiling (1)
- transient regulatory T-cell targeting (1)
- tumor necrosis factor (TNF) (1)
- tyrosine-kinase inhibitor (1)
- verteporfin (1)
- volumetric absorptive micro-sampling (VAMS) (1)
- yoga (1)
- γδ T cells (1)
Institute
- Medizinische Klinik und Poliklinik II (50) (remove)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 2016 FGR 0053 (1)
The genetic modification of T cells for the expression a chimeric antigen receptor (CAR) endows them with a new specificity for an antigen. Adoptive immunotherapy with CD19-CAR T cells has achieved high rates of sustained complete remissions in B cell malignancies. However, the downregulation or loss of the targeted antigen after mono-specific CAR T cell therapy, e.g. against CD19 or CD22, has been reported. Targeting multiple antigens on tumour cells, sequentially or simultaneously, could overcome this limitation. Additionally, targeting multiple antigens with CAR T cells could drive the translation from hematologic malignancies to prevalent solid cancers, which often express tumour-associated antigens heterogeneously. We hypothesised that expression of a universal CAR, which can be programmed with hapten-like molecules, could endow T cells with specificities for multiple antigens.
In this study we introduce a novel chemically programmable CAR (cpCAR) based on monoclonal antibody h38C2. Our data show, that cpCARs form a reversible chemical bond to molecules containing a diketone-group and therefore can be programmed to acquire multiple specificities. We programmed cpCAR T cells with hapten-like compounds against integrins αvβ3 and α4β1 as well as the folate receptor. We observed tumour cell lysis, IFN ɣ and IL-2 production and proliferation of programmed cpCAR T cells against tumour cells expressing the respective target antigen in vitro.
As a reference to cpCARs programmed against αvβ3, we further introduced novel conventional αvβ3-CARs. These CARs, based on humanised variants of monoclonal antibody LM609 (hLM609), directly bind to integrin αvβ3 via their scFv. The four αvβ3-CAR constructs comprised either an scFv with higher affinity (hLM609v7) or lower affinity (hLM609v11) against αvβ3 integrin and either a long (IgG4 hinge, CH2, CH3) or short (IgG4 hinge) extracellular spacer. We selected the hLM609v7-CAR with short spacer, which showed potent anti-tumour reactivity both in vitro and in a murine xenograft model, for comparison with the cpCAR programmed against αvβ3. Our data show specific lysis of αvβ3-positive tumour cells, cytokine production and proliferation of both hLM609-CAR T cells and cpCAR T cells in vitro. However, conventional hLM609-CAR T cells mediated stronger anti-tumour effects compared to cpCAR T cells in the same amount of time. In line with the in vitro data, complete destruction of tumour lesions in a murine melanoma xenograft model was only observed for mice treated with conventional αvβ3-CAR T cells.
Collectively, we introduce a cpCAR, which can be programmed against multiple tumour antigens, and hLM609-CARs specific for the integrin αvβ3. The cpCAR technology bears the potential to counteract current limitations, e.g. antigen loss, of current monospecific CAR T cell therapy. Targeting αvβ3 integrin with CAR T cells could have clinical applications in the treatment of solid malignancies, because αvβ3 is not only expressed on a variety of solid malignancies, but also on tumour-associated vasculature and fibroblast.
(1) Background: We aimed to quantitatively investigate [\(^{68}\)Ga]Ga-FAPI-04 uptake in normal organs and to assess a relationship with the extent of FAPI-avid tumor burden. (2) Methods: In this single-center retrospective analysis, thirty-four patients with solid cancers underwent a total of 40 [\(^{68}\)Ga]Ga-FAPI-04 PET/CT scans. Mean standardized uptake values (SUV\(_{mean}\)) for normal organs were established by placing volumes of interest (VOIs) in the heart, liver, spleen, pancreas, kidneys, and bone marrow. Total tumor burden was determined by manual segmentation of tumor lesions with increased uptake. For tumor burden, quantitative assessment included maximum SUV (SUV\(_{max}\)), tumor volume (TV), and fractional tumor activity (FTA = TV × SUV\(_{mean}\)). Associations between uptake in normal organs and tumor burden were investigated by applying Spearman's rank correlation coefficient. (3) Results: Median SUV\(_{mean}\) values were 2.15 in the pancreas (range, 1.05–9.91), 1.42 in the right (range, 0.57–3.06) and 1.41 in the left kidney (range, 0.73–2.97), 1.2 in the heart (range, 0.46–2.59), 0.86 in the spleen (range, 0.55–1.58), 0.65 in the liver (range, 0.31–2.11), and 0.57 in the bone marrow (range, 0.26–0.94). We observed a trend towards significance for uptake in the myocardium and tumor-derived SUV\(_{max}\) (ρ = 0.29, p = 0.07) and TV (ρ = −0.30, p = 0.06). No significant correlation was achieved for any of the other organs: SUV\(_{max}\) (ρ ≤ 0.1, p ≥ 0.42), TV (ρ ≤ 0.11, p ≥ 0.43), and FTA (ρ ≤ 0.14, p ≥ 0.38). In a sub-analysis exclusively investigating patients with high tumor burden, significant correlations of myocardial uptake with tumor SUV\(_{max}\) (ρ = 0.44; p = 0.03) and tumor-derived FTA with liver uptake (ρ = 0.47; p = 0.02) were recorded. (4) Conclusions: In this proof-of-concept study, quantification of [\(^{68}\)Ga]Ga-FAPI-04 PET showed no significant correlation between normal organs and tumor burden, except for a trend in the myocardium. Those preliminary findings may trigger future studies to determine possible implications for treatment with radioactive FAP-targeted drugs, as higher tumor load or uptake may not lead to decreased doses in the majority of normal organs.
Background
Liver steatosis is often observed in chronic HCV infection and associated to genotype or comorbidities. NAFLD is an important risk factor for end-stage liver disease. We aimed to analyse the course of NAFLD as a concomitant disease in a cohort of HCV patients.
Methods
The German Hepatitis C-Registry is a national multicenter real-world cohort. In the current analysis, 8789 HCV patients were included and separated based on the presence of steatosis on ultrasound and/or histology. Fibrosis progression was assessed by transient elastography (TE), ultrasound or non-invasive surrogate scores.
Results
At the time of study inclusion 12.3% (n = 962) of HCV patients presented with steatosis (+S) (higher rate in GT-3). Diabetes mellitus was more frequent in GT-1 patients. HCV patients without steatosis (-S) had a slightly higher rate of fibrosis progression (FP) over time (30.3%) in contrast to HCV patients +S (26%). This effect was mainly observed in GT-3 patients (34.4% vs. 20.6%). A larger decrease of ALT, AST and GGT from baseline to FU-1 (4–24 weeks after EOT) was found in HCV patients (without FP) +S compared to -S. HCV patients -S and with FP presented more often metabolic comorbidities with a significantly higher BMI (+0.58kg/m\(^{2}\)) compared to patients -S without FP. This was particularly pronounced in patients with abnormal ALT.
Conclusion
Clinically diagnosed steatosis in HCV patients does not seem to contribute to significant FP in this unique cohort. The low prevalence of steatosis could reflect a lower awareness of fatty liver in HCV patients, as patients -S and with FP presented more metabolic risk factors.
Background
Endoscopic vacuum therapy (EVT) is an evidence-based option to treat anastomotic leakages of the upper gastrointestinal (GI) tract, but the technical challenges and clinical outcomes of patients with large defects remain poorly described.
Methods
All patients with leakages of the upper GI tract that were treated with endoscopic negative pressure therapy at our institution from 2012–2021 were analyzed. Patients with large defects (>30 mm) as an indicator of complex treatment were compared to patients with smaller defects (control group).
Results
Ninety-two patients with postoperative anastomotic or staplerline leakages were identified, of whom 20 (21.7%) had large defects. Compared to the control group, these patients required prolonged therapy (42 vs. 14 days, p < 0.001) and hospital stay (63 vs. 26 days, p < 0.001) and developed significantly more septic complications (40 vs. 17.6%, p = 0.027.) which often necessitated additional endoscopic and/or surgical/interventional treatments (45 vs. 17.4%, p = 0.007.) Nevertheless, a resolution of leakages was achieved in 80% of patients with large defects, which was similar compared to the control group (p = 0.42). Multiple leakages, especially on the opposite side, along with other local unfavorable conditions, such as foreign material mass, limited access to the defect or extensive necrosis occurred significantly more often in cases with large defects (p < 0.001).
Conclusions
Overall, our study confirms that EVT for leakages even from large defects of the upper GI tract is feasible in most cases but comes with significant technical challenges.
Objective
At high altitude (HA), acute mountain sickness (AMS) is accompanied by neurologic and upper gastrointestinal symptoms (UGS). The primary aim of this study was to test the hypothesis that delayed gastric emptying (GE), assessed by \(^{13}\)C-octanoate breath testing (OBT), causes UGS in AMS. The secondary aim was to assess post-gastric mechanisms of OBT, which could confound results under these conditions, by determination of intermediary metabolites, gastrointestinal peptides, and basal metabolic rate.
Methods
A prospective trial was performed in 25 healthy participants (15 male) at 4559 m (HA) and at 490 m (Zurich). GE was assessed by OBT (428 kcal solid meal) and UGS by visual analogue scales (VAS). Blood sampling of metabolites (glucose, free fatty acids (FFA), triglycerides (TG), beta-hydroxyl butyrate (BHB), L-lactate) and gastrointestinal peptides (insulin, amylin, PYY, etc.) was performed as well as blood gas analysis and spirometry. Statistical analysis: variance analyses, bivariate correlation, and multilinear regression analysis.
Results
After 24 h under hypoxic conditions at HA, participants developed AMS (p < 0.001). \(^{13}\)CO\(_{2}\) exhalation kinetics increased (p < 0.05) resulting in reduced estimates of gastric half-emptying times (p < 0.01). However, median resting respiratory quotients and plasma profiles of TG indicated that augmented beta-oxidation was the main predictor of accelerated \(^{13}\)CO\(_{2}\)-generation under these conditions.
Conclusion
Quantification of \(^{13}\)C-octanoate oxidation by a breath test is sensitive to variation in metabolic (liver) function under hypoxic conditions. \(^{13}\)C-breath testing using short-chain fatty acids is not reliable for measurement of gastric function at HA and should be considered critically in other severe hypoxic conditions, like sepsis or chronic lung disease.
Background
Machine learning, especially deep learning, is becoming more and more relevant in research and development in the medical domain. For all the supervised deep learning applications, data is the most critical factor in securing successful implementation and sustaining the progress of the machine learning model. Especially gastroenterological data, which often involves endoscopic videos, are cumbersome to annotate. Domain experts are needed to interpret and annotate the videos. To support those domain experts, we generated a framework. With this framework, instead of annotating every frame in the video sequence, experts are just performing key annotations at the beginning and the end of sequences with pathologies, e.g., visible polyps. Subsequently, non-expert annotators supported by machine learning add the missing annotations for the frames in-between.
Methods
In our framework, an expert reviews the video and annotates a few video frames to verify the object’s annotations for the non-expert. In a second step, a non-expert has visual confirmation of the given object and can annotate all following and preceding frames with AI assistance. After the expert has finished, relevant frames will be selected and passed on to an AI model. This information allows the AI model to detect and mark the desired object on all following and preceding frames with an annotation. Therefore, the non-expert can adjust and modify the AI predictions and export the results, which can then be used to train the AI model.
Results
Using this framework, we were able to reduce workload of domain experts on average by a factor of 20 on our data. This is primarily due to the structure of the framework, which is designed to minimize the workload of the domain expert. Pairing this framework with a state-of-the-art semi-automated AI model enhances the annotation speed further. Through a prospective study with 10 participants, we show that semi-automated annotation using our tool doubles the annotation speed of non-expert annotators compared to a well-known state-of-the-art annotation tool.
Conclusion
In summary, we introduce a framework for fast expert annotation for gastroenterologists, which reduces the workload of the domain expert considerably while maintaining a very high annotation quality. The framework incorporates a semi-automated annotation system utilizing trained object detection models. The software and framework are open-source.
The COVID-19 pandemic has resulted in large numbers of patients requiring critical care management. With the established association between severe respiratory virus infection and invasive pulmonary aspergillosis (7.6% for COVID-19-associated pulmonary aspergillosis (CAPA)), the pandemic places a significant number of patients at potential risk from secondary invasive fungal disease. We described a case of CAPA with substantial supporting mycological evidence, highlighting the need to employ strategic diagnostic algorithms and weighted definitions to improve the accuracy in diagnosing CAPA.
Despite available diagnostic tests and recent advances, diagnosis of pulmonary invasive aspergillosis (IPA) remains challenging. We performed a longitudinal case-control pilot study to identify host-specific, novel, and immune-relevant molecular candidates indicating IPA in patients post allogeneic stem cell transplantation (alloSCT). Supported by differential gene expression analysis of six relevant in vitro studies, we conducted RNA sequencing of three alloSCT patients categorized as probable IPA cases and their matched controls without Aspergillus infection (66 samples in total). We additionally performed immunoassay analysis for all patient samples to gain a multi-omics perspective. Profiling analysis suggested LGALS2, MMP1, IL-8, and caspase-3 as potential host molecular candidates indicating IPA in investigated alloSCT patients. MMP1, IL-8, and caspase-3 were evaluated further in alloSCT patients for their potential to differentiate possible IPA cases and patients suffering from COVID-19-associated pulmonary aspergillosis (CAPA) and appropriate control patients. Possible IPA cases showed differences in IL-8 and caspase-3 serum levels compared with matched controls. Furthermore, we observed significant differences in IL-8 and caspase-3 levels among CAPA patients compared with control patients. With our conceptual work, we demonstrate the potential value of considering the human immune response during Aspergillus infection to identify immune-relevant molecular candidates indicating IPA in alloSCT patients. These human host candidates together with already established fungal biomarkers might improve the accuracy of IPA diagnostic tools.
Despite high levels of distress, family caregivers of patients with cancer rarely seek psychosocial support and Internet-based interventions (IBIs) are a promising approach to reduce some access barriers. Therefore, we developed a self-guided IBI for family caregivers of patients with cancer (OAse), which, in addition to patients' spouses, also addresses other family members (e.g., adult children, parents). This study aimed to determine the feasibility of OAse (recruitment, dropout, adherence, participant satisfaction). Secondary outcomes were caregivers’ self-efficacy, emotional state, and supportive care needs. N = 41 family caregivers participated in the study (female: 65%), mostly spouses (71%), followed by children (20%), parents (7%), and friends (2%). Recruitment (47%), retention (68%), and adherence rates (76% completed at least 4 of 6 lessons) support the feasibility of OAse. Overall, the results showed a high degree of overall participant satisfaction (96%). There were no significant pre-post differences in secondary outcome criteria, but a trend toward improvement in managing difficult interactions/emotions (p = .06) and depression/anxiety (p = .06). Although the efficacy of the intervention remains to be investigated, our results suggest that OAse can be well implemented in caregivers’ daily lives and has the potential to improve family caregivers’ coping strategies.
Using data from the German Hepatitis C-Registry (Deutsche Hepatitis C-Register, DHC-R), we report the real-world safety and effectiveness of glecaprevir/pibrentasvir (GLE/PIB) treatment and its impact on patient-reported outcomes (PROs) in underserved populations who are not typically included in clinical trials, yet who will be crucial for achieving hepatitis C virus (HCV) elimination. The DHC-R is an ongoing, non-interventional, multicenter, prospective, observational cohort study on patients treated for chronic HCV infection in Germany. The data cutoff was 17 January 2021. The primary effectiveness endpoint was sustained virologic response at post-treatment Week 12 (SVR12). Safety outcomes were assessed in all patients receiving GLE/PIB. PROs were assessed using the SF-36 survey. Of 2354 patients, 1964 had valid SVR12 data (intention-to-treat analysis). Of these, 1905 (97.0%) achieved SVR12 with rates similar across the comorbidities analyzed, except for people who actively use drugs (PWUD (active)) (86.4%). Excluding those who discontinued treatment and did not achieve SVR12, or were reinfected with HCV, the rate was 99.3%, with similar results regardless of comorbidity. PWUD (active) and those with psychiatric disorders had the most meaningful improvements in PROs. Adverse events (AEs) occurred in 631/2354 patients (26.8%), and serious AEs in 44 patients (1.9%). GLE/PIB was highly effective and well tolerated in this real-world study of patient groups key to HCV elimination.